FDA-cleared profile

XIDF-AWS801, Angio Workstation (Alphenix Workstation), V9.5

Canon Medical Systems Corporation · Fluoroscopy/Angiography · FDA-cleared (510(k))

Two-dimensional and three-dimensional fluoroscopic and angiographic imaging support for selective catheter procedures across cardiac, vascular, neurovascular, thoracic, abdominal, pelvic, and other interventional anatomy.

Clinical role
Acquisition, reconstruction, display, and procedural imaging support on the Alphenix workstation.
Images and patients
Fluoroscopy/Angiography · Vascular
Key limitation
Use requires combination with an interventional angiography system and is limited to selective catheter angiography procedures in the stated whole-body scope.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyFluoroscopy/Angiography · Vascular
  • Workflow roleAcquisition, reconstruction, display, and procedural imaging support on the Alphenix workstation.
  • Required inputCompatible fluoroscopic and angiographic image data acquired on the labeled Alphenix system.
  • Output and human actionTwo-dimensional and three-dimensional angiographic visualizations and supported procedural views.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Two-dimensional and three-dimensional fluoroscopic and angiographic imaging support for selective catheter procedures across cardiac, vascular, neurovascular, thoracic, abdominal, pelvic, and other interventional anatomy.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Acquisition, reconstruction, display, and procedural imaging support on the Alphenix workstation.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Compatible fluoroscopic and angiographic image data acquired on the labeled Alphenix system.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Two-dimensional and three-dimensional angiographic visualizations and supported procedural views.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Interventional cardiology, radiology, oncology, and neurovascular angiography environments.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Use requires combination with an interventional angiography system and is limited to selective catheter angiography procedures in the stated whole-body scope.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication establishes the required system combination and procedure boundary without adding an unsupported user-responsibility claim.

Evidence summary
Risk analysis and verification/validation bench testing addressed the V9.5 software changes; the packet states there are no new indications for use or intended uses.
  • Exact FDA submission
  • Checked 2026-09-19

The exact summary describes the V9.5 testing and unchanged intended-use boundary.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Risk analysis and verification/validation bench testing addressed the V9.5 software changes; the packet states there are no new indications for use or intended uses.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact summary describes the V9.5 testing and unchanged intended-use boundary.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232526. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Compatible fluoroscopic and angiographic image data acquired on the labeled Alphenix system.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K232526: XIDF-AWS801, Angio Workstation (Alphenix Workstation), V9.5

  2. Routing

    Source context, not route validation: The software is an Alphenix workstation component integrated with the compatible Canon angiography system; external enterprise interfaces require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K232526: XIDF-AWS801, Angio Workstation (Alphenix Workstation), V9.5

  3. AI processing

    Source context, not route validation: The exact FDA package describes software in the XIDF-AWS801 Angio Workstation, which is used in combination with an Alphenix, Infinix-i or INFX series interventional angiography system. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Software in the Angio Workstation was changed from V9.3 to V9.5 via Internal Documentation" … "The Angio Workstation (XIDF-AWS801) is used in combination with an interventional angiography system (Alphenix series systems, Infinix-i series systems and INFX series systems)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K232526: XIDF-AWS801, Angio Workstation (Alphenix Workstation), V9.5

  4. Returned objects

    Source context, not route validation: Two-dimensional and three-dimensional angiographic visualizations and supported procedural views.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K232526: XIDF-AWS801, Angio Workstation (Alphenix Workstation), V9.5

  5. Viewer/worklist/report

    Unresolved route: Two-dimensional and three-dimensional angiographic visualizations and supported procedural views.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K232526: XIDF-AWS801, Angio Workstation (Alphenix Workstation), V9.5

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes software in the XIDF-AWS801 Angio Workstation, which is used in combination with an Alphenix, Infinix-i or INFX series interventional angiography system. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software in the Angio Workstation was changed from V9.3 to V9.5 via Internal Documentation" … "The Angio Workstation (XIDF-AWS801) is used in combination with an interventional angiography system (Alphenix series systems, Infinix-i series systems and INFX series systems)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The software is an Alphenix workstation component integrated with the compatible Canon angiography system; external enterprise interfaces require confirmation.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.

Current product-family workflow context

Canon describes the Alphenix family as interventional angiography systems supporting cardiology, interventional radiology and oncology, and neurovascular procedures with planning, imaging, and dose-optimization tools.

product family · checked 2026-09-08

Confirm exact-release availability, interfaces, hosting, security, support, and commercial terms during procurement.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232526
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Fluoroscopy/Angiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Vascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication gives a whole-body procedure scope; it does not establish the narrower anatomy label Vascular. Controlled directory display reconciled from exact FDA wording: Whole body, including heart, chest, abdomen, brain, and extremity. -> Vascular.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-09-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
17Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K232526 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 2 history items

Source ledger

  1. FDA K232526: XIDF-AWS801, Angio Workstation (Alphenix Workstation), V9.5

    U.S. Food and Drug Administration - Published 2023-09-12 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. openFDA exact recall query for K232526

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  7. Alphenix angiography systems

    Canon Medical Systems - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow, implementationCapabilities

  8. Canon Medical: Medical Imaging Cybersecurity

    Canon Medical Systems USA - Accessed 2026-10-26

    Scope: security

Research history

  1. K232526 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K252099

Trinias

Shimadzu Corporation

Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24
FDA-cleared K253614

EchoNavigator R5.0

Philips Medical Systems Nederland B.V.

Authorized purpose: EchoNavigator R5.0 supports an interventionalist or surgeon during cardiovascular treatment by combining live X-ray and live echocardiographic information.

Modality
Fluoroscopy/Angiography
Anatomy
Heart and cardiovascular structures
Decision
2026-03-17
FDA-cleared K253584

Alphenix, INFX-8000V/B, INFX-8000V/S, V9.6 with aEvolve Imaging (FOV Extension)

Canon Medical Systems Corporation

Authorized purpose: Alphenix and INFX-8000V/B,S V9.6 with aEvolve FOV Extension are digital radiography and fluoroscopy systems for diagnostic and interventional angiography, with labeled real-time AI Denoising and MFP signal-enhancement functions.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, brain, abdomen, and lower-extremity vessels
Decision
2026-03-10
FDA-cleared K252500

CARA System

Cara Medical, Ltd.

Authorized purpose: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2026-02-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history